CTX110
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Malignancy
Conditions
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
Trial Timeline
Jul 22, 2019 → Oct 4, 2024
NCT ID
NCT04035434About CTX110
CTX110 is a phase 1/2 stage product being developed by CRISPR Therapeutics for B-cell Malignancy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04035434. Target conditions include B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Malignancy were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04035434 | Phase 1/2 | Terminated |
Competing Products
20 competing products in B-cell Malignancy